About Us

We're here to transform the lives of people affected by neuromuscular disease.

Press Releases

  • Former MDA President and CEO Gerald C. Weinberg Dies

    The following statement is in response to the passing of former MDA President and CEO Gerald C. Weinberg on Tuesday, May 23, 2017. Jerry, who was 87 years old, was an integral member of the organization for 54 years, having helped launch MDA, advance MDA's life-saving mission and the Labor Day Telethon into national prominence. He served as President and CEO from 2006 – 2011.


  • Harley-Davidson Executives to Roll Out of Milwaukee for Historic 30th Anniversary of MDA Ride for Life

    The legacy ride celebrates support for families affected by muscular dystrophy beyond $100 million

  • ReveraGen BioPharma Receives FDA Fast Track Designation for Vamorolone for the Treatment of Duchenne Muscular Dystrophy

    ROCKVILLE, Maryland, March 24, 2017

  • PTC Therapeutics Announces Agreement to Acquire Emflaza™ for the Treatment of Duchenne Muscular Dystrophy in U.S.

    • Emflaza is the first treatment approved in the U.S. for DMD patients 5 years and older, regardless of genetic mutation

    • Aligns with PTC's mission and commitment to the DMD community

    • $140 million upfront consideration (comprised of cash and PTC common stock) plus potential contingent payments based on net sales and single milestone payment

    • PTC to host investor conference call today, March 16, 2017 at 8:30 am ET

  • MDA Awards $96,360 to Izumi Biosciences

    Investment will support development of ALS drug “enhancer”

    CHICAGO, March 10, 2017 – The Muscular Dystrophy Association is pleased to announce the award of an MDA Venture Philanthropy (MVP) grant, totaling $96,360 to Lexington, Mass.-based Izumi Biosciences, Inc., to fund early-stage development of IZ10023, a type of drug called a pharmacokinetic (PK) enhancer,” for use in people with ALS (amyotrophic lateral sclerosis) who are taking riluzole.

  • MDA Awards More than $7 Million in New Research Grants

    New investment builds on recent breakthroughs with availability of three new neuromuscular disease drugs

    CHICAGO, March 9, 2017 – The Muscular Dystrophy Association today announced the award of 29 new research and development grants totaling more than $7 million and targeted to impact the state of the science and accelerate the development of treatments for muscular dystrophy, ALS and related life-threatening diseases.